Investors

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

NASDAQ: SNDX
$ 13.84 +0.66 (5.01%)
Day High: 13.97
Day Low:  13.09
Volume:    66,232
4:00 PM ET
07.21.17

Delayed ~20 min., by eSignal.

Press Releases


Events & Presentations